The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ended March 2025; First-Quarter Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ending March 2026; Second-Quarter Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ending March 2026; Third-Quarter Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ending March 2026
Open the original documentFinancial results summaries and quarterly financial results summaries previously disclosed for prior fiscal years; revenue, operating income, ordinary income, net income attributable to owners of the parent, total assets, and net assets in the consolidated financial statements
The impact of these corrections on financial results is as follows.
In the fiscal year ended March 2025, inventory including manufacturing-related materials and investigational drugs that was not scheduled for future use was expensed, but some of the inventory had already been expensed. In addition, construction in progress had been recorded twice at certain subsidiaries.
| Item | Details |
|---|---|
| Disclosure subject to correction | Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ended March 2025; First-Quarter Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ending March 2026; Second-Quarter Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ending March 2026; Third-Quarter Financial Results Summary [Japanese GAAP] (Consolidated) for the fiscal year ending March 2026 |
| Location of correction | Financial results summaries and quarterly financial results summaries previously disclosed for prior fiscal years; revenue, operating income, ordinary income, net income attributable to owners of the parent, total assets, and net assets in the consolidated financial statements |
| Details of correction | For the fiscal year ended March 2025: operating income increased by ¥430 million, ordinary income by ¥430 million, net income attributable to owners of the parent by ¥299 million, and net assets by ¥299 million. For the third quarter of the fiscal year ending March 2026: operating income increased by ¥50 million, ordinary income by ¥50 million, net income attributable to owners of the parent by ¥35 million, and net assets by ¥334 million |
| Reason for correction | In the fiscal year ended March 2025, inventory including manufacturing-related materials and investigational drugs that was not scheduled for future use was expensed, but some of the inventory had already been expensed. In addition, construction in progress had been recorded twice at certain subsidiaries. |
| Impact on Business Performance | The impact of these corrections on financial results is as follows. |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fiscal year ended March 2025, inventory including manufacturing-related materials and investigational drugs that were not scheduled for future use was expensed, but some of the items had already been expensed. In addition, construction in progress had been recorded twice at certain subsidiaries.